← Back to Analyst Consensus 
AVLN Buy
Avalyn Pharma Inc.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 2, 2026 | Raymond James | initiate | — → Outperform | — | 54% |
| Aug 13, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| May 26, 2026 | Evercore ISI Group | initiate | — → Outperform | — | 58% |
| May 26, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| May 26, 2026 | Morgan Stanley | initiate | — → Overweight | — | 54% |
Price Target Trend
Jun 3, 2026 Latest: $61.8 Oct 24, 2026
EPS Estimates
+1q $-0.72
Lo: $-0.72 Hi: $-0.72
1 analysts +1y $-2.58
Lo: $-2.58 Hi: $-2.58
1 analysts 0y $-2.69
Lo: $-2.69 Hi: $-2.69
1 analysts 0q $-0.75
Lo: $-0.79 Hi: $-0.71
2 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days